Amarin Corp ADR (AMRN) Stock Price, Quote & News

Company Profile

Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally through wholesalers, selected regional wholesalers, and specialty p...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 353 0 166 99020

Website: www.amarincorp.com

Address:

One Central Plaza, 5th Floor 36 Dame Street, Dublin, Ireland

declanaidan Feb. 3 at 10:05 PM

$AMRN Gotta love this Amarin trading. Down over 10% after hours...on one share!

1 · Reply

StevieMoMoney Feb. 3 at 9:45 PM

$AMRN how did they pull off after hours $13.47. 1 share

0 · Reply

CaptBeer Feb. 3 at 5:02 PM

$AMRN OT NVO crashing on ER Report. 😵‍💫

1 · Reply

ians Feb. 3 at 4:20 PM

$AMRN Positive EPS of +$0.03 forecasted. The first in a long time. And hopefully just a start. Get that $120-150 BO PT👍🍀💎

1 · Reply

crayonboy Feb. 3 at 2:08 PM

$AMRN how in the world are we not at $15 at the very least?? Crazy! I need to get off of this rollercoaster. Been on for more than 12 years and it’s killing me!

3 · Reply

buygreensellredchop Feb. 3 at 11:14 AM

$AMRN The never ending story of AMRN... Cant wait for this ticker to be retired..

0 · Reply

declanaidan Feb. 2 at 11:36 PM

$AMRN Riddle me this. With all the speculation about a BO of Amarin and pps laquiishing here in 14s, below COH, why would not a potential suito, NVS?, just come out and offer $30 pps, 2x? Not that we would accept that, but forces the hand of Sarissa Denner. If offerred, Amarin would have to report they received unsolicited offer, and then justify, finally, why not to accept it?????

3 · Reply

SanDiegoLiving Feb. 2 at 8:37 PM

$AMRN 🧾⚖️ ANTITRUST UPDATE — MOTIONS DENIED, CASES CONTINUE (PROCEDURAL, NOT MERITS) Doc 210 is now filed in the Teva & Apotex antitrust cases. What happened 👇 The court DENIED Amarin’s request to dismiss the cases at the pleadings stage. What that means: ➡️ Lawsuits move into the next phase ➡️ No ruling on liability ➡️ No facts found ➡️ No injunction or damages decision This is not the outcome investors were hoping for, but it is also not a merits loss. 💡 Important caveat The written opinion referenced in the order is not yet accessible, so the Court’s reasoning and the scope of surviving claims cannot be evaluated yet. That opinion will determine: 🔍 How broad discovery gets 🔍 How durable the claims are 🔍 How real the risk is for valuation or M&A Without the opinion, this changes posture but not conclusions. I’ll provide an update once it’s accessible.

1 · Reply

Flyfishingstocks Feb. 2 at 6:08 PM

$AMRN Buyback not a good idea? "Combining a RS split with a subsequent share buyback is considered a high-risk, negative signal, indicating financial distress vs strength and often results in further price declines and shareholder losses. *Signals Distress: Reverse splits are typically used by struggling companies to boost low share prices, often seen as a sign of trouble. Artificially Inflates Value: This combination does not change the company's underlying value, but consolidates shares to make the price appear higher. *High-Risk to Investors: The new, higher price often does not "stick," leading to further losses. *Liquidity Reduction: A reverse split reduces the number of shares, which can decrease market liquidity and increase volatility. *Buyback Concerns: Using company cash for a buyback immediately after a reverse split can be viewed as an attempt to manipulate the share price rather than a sign of healthy capital allocation.

2 · Reply

Novo1 Feb. 2 at 5:32 PM

$AMRN before anyone gets “infatuated” with $AMRN based on @Merlintrader’s “wudda”, “shudda”, “cudda” analysis of 2026 as a turnaround year…….remember, SCOTUS AGREED TO TAKE THE COMPANY’S APPEAL ON A JUDGE’S RULING THAT THERE IS NOTHING TO DECIDE WHICH WOULD REQUIRE A TRIAL! If SCOTUS upholds the “Judgment on the Pleadings”, there is no trial. Conversely, if SCOTUS reverses, we are in for a long term trial and appeals. Given the company’s long and less than distinguished legal history, what do you think will be the probable outcome??

1 · Reply

US Supreme Court to hear 'skinny label' patent fight involving Amarin

Jan 9, 2026, 7:00 AM EST - 25 days ago

Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company's VASCEPA®/VAZKEPA® (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization

Nov 9, 2025, 4:15 PM EST - 3 months ago

New REDUCE-IT® Aspirin Analysis Presented at AHA Scientific Sessions 2025 Reinforces VASCEPA®/VAZKEPA® (Icosapent Ethyl) Reduced Cardiovascular Events in High-Risk Patients

Nov 3, 2025, 8:30 AM EST - 3 months ago

Amarin To Present New Analyses Affirming Robustness of Data from REDUCE-IT and Additional Mechanisms of Action of Eicosapentaenoic Acid (EPA) at American Heart Association (AHA) Scientific Sessions 2025

Oct 29, 2025, 10:21 AM EDT - 3 months ago

Amarin Corporation plc (AMRN) Q3 2025 Earnings Call Transcript

Oct 14, 2025, 8:00 AM EDT - 4 months ago

Amarin and HLS Therapeutics Collaborate on Presenting REDUCE-IT® and EPA Mechanistic Data at the Canadian Cardiovascular Congress

Sep 29, 2025, 5:52 PM EDT - 4 months ago

Amarin: Vascepa's Global Pivot From U.S. Squeeze To International Boom

Aug 31, 2025, 8:30 AM EDT - 5 months ago

Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ESC 2025

Aug 30, 2025, 8:30 AM EDT - 5 months ago

New REDUCE-IT® Analyses Presented at ESC 2025 Include Data Showing VASCEPA®/VAZKEPA® (Icosapent Ethyl) Therapy Resulted in 9% Fewer Total Hospitalizations & Reduces Cardiovascular Disease Risk in Certain High-Risk Patient Subgroups

Aug 25, 2025, 8:00 AM EDT - 5 months ago

New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2025

Jul 30, 2025, 2:06 PM EDT - 6 months ago

Amarin Corporation plc (AMRN) Q2 2025 Earnings Call Transcript

Jul 30, 2025, 7:00 AM EDT - 6 months ago

Amarin Reports Second Quarter 2025 Financial Results

Jul 23, 2025, 7:30 AM EDT - 6 months ago

Amarin to Report Second Quarter 2025 Financial Results and Host Conference Call on July 30, 2025

Jun 24, 2025, 7:05 AM EDT - 8 months ago

RECORDATI ANNOUNCES EXCLUSIVE LICENSING & SUPPLY AGREEMENT WITH AMARIN TO COMMERCIALIZE VAZKEPA® IN EUROPE

May 7, 2025, 11:01 AM EDT - 9 months ago

Amarin Corporation plc (AMRN) Q1 2025 Earnings Call Transcript

Apr 29, 2025, 4:15 PM EDT - 10 months ago

Amarin Regains Compliance with Nasdaq Minimum Bid Price Requirement

Apr 28, 2025, 4:15 PM EDT - 10 months ago

Amarin to Report First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025

Apr 14, 2025, 10:02 AM EDT - 10 months ago

Hyatt Hotels, THOR Industries And Other Big Stocks Moving Lower On Monday

H THO ALMS CCO ECX HZO NUTX

Apr 9, 2025, 7:30 AM EDT - 10 months ago

Amarin Confirms Effective Date for 1-For-20 ADS Ratio Change

Apr 7, 2025, 7:30 AM EDT - 10 months ago

Amarin Appoints JEC Capital Partners' Michael Torok to Board of Directors

Mar 19, 2025, 12:45 PM EDT - 11 months ago

Concerned Shareholder Group Urges Amarin's Board of Directors to Initiate a Strategic Review Following Two Years of Underperformance

Mar 19, 2025, 7:30 AM EDT - 11 months ago

New Research Exploring Mechanistic Benefits of Eicosapentaenoic Acid (EPA) In Vitro on Lipoprotein(a) [Lp(a)] Oxidation and on Protein Expression in Endothelial Cells in Combination with GLP-1 Receptor Agonist to be Presented at the American College of Cardiology's (ACC) Annual Scientific Session & Expo

Mar 12, 2025, 10:30 AM EDT - 11 months ago

Amarin Corporation plc (AMRN) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 9:00 AM EST - 1 year ago

Amarin Marks Key Milestone for VASCEPA®/VAZKEPA® (Icosapent Ethyl) -- Publication of Post Hoc Analysis of REDUCE-IT in Journal of the American Heart Association Reports Benefit on Top of Cholesterol Lowering

Feb 19, 2025, 8:30 AM EST - 1 year ago

Amarin to Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 12, 2025

Dec 16, 2024, 7:00 AM EST - 1 year ago

Amarin Receives National Reimbursement for VAZKEPA® in Italy

Dec 13, 2024, 9:00 AM EST - 1 year ago

Amarin Appoints Peter Fishman Chief Financial Officer

Nov 19, 2024, 7:52 AM EST - 1 year ago

Top 3 Health Care Stocks You'll Regret Missing In Q4

SLN TERN

Oct 30, 2024, 8:50 PM EDT - 1 year ago

Amarin Corporation plc (AMRN) Q3 2024 Earnings Call Transcript

Sep 9, 2024, 7:30 AM EDT - 1 year ago

Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual European Association for the Study of Diabetes (EASD) Meeting

Aug 22, 2024, 8:30 AM EDT - 1 year ago

Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress

Jul 31, 2024, 12:28 PM EDT - 1 year ago

Amarin Corporation plc (AMRN) Q2 2024 Earnings Call Transcript

Jul 31, 2024, 7:00 AM EDT - 1 year ago

Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update

Jul 17, 2024, 4:15 PM EDT - 1 year ago

Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Portugal

Jul 17, 2024, 8:00 AM EDT - 1 year ago

Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024

Jul 8, 2024, 7:30 AM EDT - 1 year ago

Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR)

Jun 7, 2024, 7:16 PM EDT - 1 year ago

LA BOUTIQUE Opens Flagship Store at Gaysorn Amarin: The New Must-Visit Destination in Bangkok

Jun 4, 2024, 7:30 AM EDT - 1 year ago

Amarin Board of Directors Announces CEO Transition

May 28, 2024, 8:15 AM EDT - 1 year ago

Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A.

May 6, 2024, 8:00 AM EDT - 1 year ago

Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference

May 1, 2024, 10:43 AM EDT - 1 year ago

Amarin Corporation plc (AMRN) Q1 2024 Earnings Call Transcript

May 1, 2024, 7:00 AM EDT - 1 year ago

Amarin Reports First Quarter 2024 Business Update and Financial Results

Apr 24, 2024, 2:00 PM EDT - 1 year ago

Amarin Applauds HealthyWomen's Citizen's Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event

Apr 22, 2024, 8:00 AM EDT - 1 year ago

Amarin Announces Results of Annual General Meeting of Shareholders

Apr 15, 2024, 8:00 AM EDT - 1 year ago

Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024

Apr 8, 2024, 8:00 AM EDT - 1 year ago

Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24

Apr 6, 2024, 3:30 PM EDT - 1 year ago

New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups

Apr 3, 2024, 8:00 AM EDT - 1 year ago

Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe

Mar 25, 2024, 8:00 AM EDT - 2 years ago

Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology's (ACC) Annual Scientific Session & Expo

Feb 29, 2024, 10:18 AM EST - 2 years ago

Amarin Corporation plc (AMRN) Q4 2023 Earnings Call Transcript

declanaidan Feb. 3 at 10:05 PM

$AMRN Gotta love this Amarin trading. Down over 10% after hours...on one share!

1 · Reply

StevieMoMoney Feb. 3 at 9:45 PM

$AMRN how did they pull off after hours $13.47. 1 share

0 · Reply

CaptBeer Feb. 3 at 5:02 PM

$AMRN OT NVO crashing on ER Report. 😵‍💫

1 · Reply

ians Feb. 3 at 4:20 PM

$AMRN Positive EPS of +$0.03 forecasted. The first in a long time. And hopefully just a start. Get that $120-150 BO PT👍🍀💎

1 · Reply

crayonboy Feb. 3 at 2:08 PM

$AMRN how in the world are we not at $15 at the very least?? Crazy! I need to get off of this rollercoaster. Been on for more than 12 years and it’s killing me!

3 · Reply

buygreensellredchop Feb. 3 at 11:14 AM

$AMRN The never ending story of AMRN... Cant wait for this ticker to be retired..

0 · Reply

declanaidan Feb. 2 at 11:36 PM

3 · Reply

SanDiegoLiving Feb. 2 at 8:37 PM

1 · Reply

Flyfishingstocks Feb. 2 at 6:08 PM

2 · Reply

Novo1 Feb. 2 at 5:32 PM

1 · Reply

DoMoreCharity Feb. 2 at 4:44 PM

$AMRN https://x.com/icorvilud/status/2018053406858879086?s=46

0 · Reply

SanDiegoLiving Feb. 1 at 9:31 PM

$AMRN 🫀📖 EPA IS NOW TAUGHT AS PART OF NHS PREVENTION — WHAT THAT SIGNALS At a UK GP trainee teaching session, prevention was taught through therapies the NHS already expects clinicians to use. These were medicines with NICE backing and established clinical pathways. The grouping was deliberate. 🧬 LDL lowering therapies 🩸 GLP 1 receptor agonists 🫀 SGLT2 inhibitors 💊 ACE inhibitors and ARBs 🟠 Icosapent ethyl EPA EPA was not presented as an exception or specialist choice. It was taught in the same outcomes based category as drugs known to reduce cardiovascular events and all cause mortality. This is how NHS practice actually changes. New prescribing habits are formed during training, before guidelines are revised and before utilization shows up in the data. When EPA is taught as part of prevention rather than as a lipid add on, its use expands by default. That process is already visible and underway.

0 · Reply

SanDiegoLiving Feb. 1 at 2:36 AM

$AMRN ⏳

1 · Reply

SanDiegoLiving Jan. 31 at 10:19 PM

$AMRN 🟥🟦 NOVARTIS & RECORDATI — COORDINATED EU POSITIONING BEGINS 👀⏳ In 2026, the Spanish Society of Cardiology (SEC) launches LipidMIR, a national, in-person cardiology training program replicated across 6 cities to educate residents & early specialists. One curriculum. Repeated execution. City after city. Same structure. Same framing. Same sponsors. The content is deliberate: atherosclerotic disease framed as the “crime,” lipoproteins & dyslipidemia as mechanisms, inflammation as a core driver, & treatment approached through multi-drug combination therapy, with success defined by event reduction rather than LDL targets alone. Now look at the sponsor panel 👇 Across every city, only 2 pharma names appear: 🟥 Recordati 🟦 Novartis Recordati operates as the EU cardiovascular bridge. Novartis owns the LDL foundation. Seeing the same two names reappear city after city signals ecosystem alignment. You really think I’ve given you guys every Novartis clue I’ve found? 👀🧩

3 · Reply

Merlintrader Jan. 31 at 6:38 PM

$AMRN https://www.merlintrader.com/amrn-amarin-corp-adr/

0 · Reply

biffermeister Jan. 31 at 12:06 AM

$AMRN to me it's heading for 13's... Steve the bull blocked me years ago when I besmirched amrn. My personal badge of honor.

2 · Reply

TDMF123 Jan. 30 at 9:46 PM

$ALT $AMRN $IBRX $MCRB $MSTR Never seen someone so determined and desperate to get attention. I keep seeing you take sooo much time to mention/bash @Steve_TheBull_Rogers and pretending like you don’t take his advice. For the love of god stop embarrassing yourself with your secret affection disguised..Just weird bro

4 · Reply

CaptBeer Jan. 30 at 9:16 PM

BEER GOOD $AMRN GOOD! Have a great Weekend!

0 · Reply

SlapThatAsssk Jan. 30 at 9:04 PM

$ALT $IBRX $MSTR $MCRB $AMRN 🚨 - since I’m getting continuously tagged by my biggest fan @Steve_TheBull_Rogers - today, let’s disclose some facts bout this lying 🤡 I, like Steve, posts stock, options ideas but difference is mine are free (he charges), I’m transparent on buys / sells with screenshots and I’ll admit when I’m wrong. He blocks… @Steve_TheBull_Rogers was STEALING my ideas like $IBRX , posting them on his feed, then taking credit because he had tons of losers like IRBT, AMRN, MCRB, ALT short, IBRX short and now SLV short. In fact, not ONLY was he following ME ( I never followed him) but he recommended ALL his Followers to FOLLOW ME - see below. 👇 👇 After I exposed him stealing, I immediately blocked him where’s he’s still blocked. U can see his posts on other apps like StockTracker. In every trade I went opposite him, he’s ALWAYS been wrong, me right and can’t handle it cause I live rent free in his head. Just check our feeds and the TRUTH will be told.

4 · Reply

biffermeister Jan. 30 at 8:51 PM

$AMRN don't forget to eat your salmon whilst checking amrn price. It'll keep them red blood cells from plugging things up.

0 · Reply

declanaidan Jan. 30 at 8:34 PM

$AMRN https://www.foxbusiness.com/lifestyle/thousands-cholesterol-drug-bottles-recalled-nationwide-over-manufacturing-defects

1 · Reply

bennfine Jan. 30 at 8:26 PM

$AMRN

0 · Reply

Market Cap	310.23M
Revenue (ttm)	228.61M
Net Income (ttm)	-82.18M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-35.95%
Debt to Equity Ratio	0.00

Volume	57,600
Avg Vol	89,898
Day's Range	N/A - N/A
Shares Out	20.79M
Stochastic %K	16%
Beta	0.72
Analysts	Buy
Price Target	$12.00